Eisai Limited celebrates opening of new Canadian headquarters

Company opens doors to new office in Mississauga

MISSISSAUGA, ON, Sept. 22, 2014 /CNW/ - Eisai Limited announces the official opening of its new Canadian headquarters in Mississauga, which will play a key role in supporting the expansion of Eisai Limited's geographical and patient reach.

"Our new office represents a commitment to growing our business and increasing Eisai's presence here in Canada," said Oliver Technow, President and General Manager, Eisai Limited.  "Eisai selected Mississauga for its Canadian headquarters due to its central location within the GTA, the largest economic cluster in Canada and a region well-known for its diverse and highly educated talent pool."

Eisai Limited was established on April 1, 2010, as the Canadian subsidiary of Eisai Inc., the U.S. pharmaceutical operating company of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  Eisai's global human health care (hhc) mission is to give first thought to patients and their families, and to increasing the benefits health care provides.  As part of this mission, Eisai Limited is dedicated to a tradition of genuine concern for people and is driven by the desire to meet the diverse healthcare needs of patients, their families and caregivers.  A key component to realizing this mission is to provide treatments, whenever possible, that address significant unmet medical needs. 

"Over the past four years we have had tremendous success.  We see potential for more opportunities to grow our team and to continue with our mission of putting patients first by providing medicines that help improve the lives of patients and their families," said Technow.  "It is an exciting time for the organization and we look forward to continuing our success in Canada."

About Eisai Limited
Eisai Inc. established the Canadian pharmaceutical company Eisai Limited in 2010.  As a wholly-owned subsidiary of Eisai Inc., Eisai Limited is based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.  For more information about Eisai in Canada, please visit www.eisai.ca.

About Eisai Inc.
At Eisai Inc., human health care is our goal.  We give our first thoughts to patients and their families.  As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts.  We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities.  Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders).  To learn more about Eisai Inc., please visit us at www.eisai.com/US. 

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina.  Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.  We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy.  With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology. 

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Image with caption: "Yuji Matsue, Chairman & CEO, Eisai Inc and Oliver Technow, President and General Manager, Eisai Limited pose with Mayor Hazel McCallion, City of Mississauga at the office opening event. (CNW Group/Eisai Limited)". Image available at: http://photos.newswire.ca/images/download/20140922_C3145_PHOTO_EN_5844.jpg

SOURCE: Eisai Limited

Media Inquiries: Karen Law, Eisai Limited, 905-361-7136